Media Articles Related to Velcade (Bortezomib)
Source: MedicineNet Amyloidosis Specialty [2016.09.22]
Title: Multiple Myeloma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 9/22/2016 12:00:00 AM
New drug class gives hope for better treatments for incurable myeloma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.08.10]
Australian researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma, an incurable bone marrow cancer.
Published Studies Related to Velcade (Bortezomib)
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. [2011.08.15]
BACKGROUND: A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma had been identified as a predictor of superior long-term outcome in some--but not all--studies... CONCLUSIONS: These analyses supported the possibility that a robust early M protein response is a good prognostic factor for long-term outcome of myeloma patients with relapsed and/or refractory disease receiving bortezomib or PLD + bortezomib. Copyright (c) 2011 American Cancer Society.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. [2011.08]
BACKGROUND: Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting... INTERPRETATION: Although a regimen of bortezomib plus rituximab is feasible, the improvement in progression-free survival provided by this regimen versus rituximab alone was not as great as expected. The regimen might represent a useful addition to the armamentarium, particularly for some subgroups of patients. FUNDING: Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals, Inc. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. [2011.05]
BACKGROUND: Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative. We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1.3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma... INTERPRETATION: Subcutaneous bortezomib offers non-inferior efficacy to standard intravenous administration, with an improved safety profile. FUNDING: Johnson & Johnson Pharmaceutical Research and Development, and Millennium Pharmaceuticals. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. [2011.05]
OBJECTIVES: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment... CONCLUSIONS: These results suggest a positive effect of bortezomib on bone metabolism and potentially bone healing in myeloma. (c) 2011 John Wiley & Sons A/S.
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. [2011.03.01]
CONCLUSIONS: Tipifarnib and bortezomib combination in patients with advanced leukemias was well-tolerated, demonstrated relevant target inhibition, and was associated with signals of clinical activity in patients with advanced and refractory acute leukemias. Future studies of this combination may be warranted in more selected groups of patients in whom these molecular targets are of particular importance. (c)2011 AACR.
Clinical Trials Related to Velcade (Bortezomib)
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma [Recruiting]
The purpose of this study is to assess the effects of administration of daratumumab when
combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and
dexamethasone alone, for participants with relapsed or refractory multiple myeloma.
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma [Completed]
The purpose of this study is to evaluate time to progression, overall survival, response
rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with
VELCADE vs. VELCADE monotherapy.
Study on the Safety and Effectiveness of VELCADE´┐Ż in the Treatment of Graft-Versus-Host Disease [Completed]
The purpose of this research study is to test the safety and effectiveness of VELCADE« in
the treatment of acute graft-versus-host disease (GVHD) that has not responded to steroids
or has worsened when the steroid dose was decreased. VELCADE« is a drug that inhibits
certain immune reactions that happen when lymphocytes encounter foreign substances. We are
doing this research to determine if VELCADE« may be useful in treating GVHD.
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) [Completed]
The primary purpose of this Phase I study is to evaluate the effect of the co-administration
of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib). Rifampicin will
be used to assess the effect of a strong CYP3A4 inducer and dexamethasone to assess the
effect of a relatively weak inducer. This study is also to evaluate the impact of CYP3A4
inducers on the pharmacodynamics (PD) of VELCADE and the safety profile of VELCADE.
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma [Completed]
The purpose of this study is to evaluate the safety and tolerability and to establish the
maximum tolerated dose of JNJ-26481585 combined with VELCADE and dexamethasone.
Reports of Suspected Velcade (Bortezomib) Side Effects
Neuropathy Peripheral (150),
Multiple Myeloma (89),
Fatigue (87), more >>